- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01808560
Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery
Pilot Study for Treatment of Meibomian Gland Dysfunction (MGD) Prior to Cataract Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Hoffman Estates, Illinois, United States, 60169
- Chicago Cornea Consultants, Ltd.
-
Lake Villa, Illinois, United States, 60046
- Jackson Eye
-
-
Massachusetts
-
Winchester, Massachusetts, United States, 01890
- Charles River Eye Associates
-
-
Minnesota
-
Stillwater, Minnesota, United States, 55082
- Associated Eye Care
-
-
Missouri
-
Saint Louis, Missouri, United States, 63131
- Ophthalmology Consultants, Ltd.
-
-
Pennsylvania
-
Hanover, Pennsylvania, United States, 17833
- The May Eye Care Center
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 29464
- Carolina EyeCare Physicians, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 55 to 85 years of age
- Must be able to comply with protocol including study randomization; completion of planned bilateral cataract surgery; no use of other MGD or dry eye treatments during the study; and attendance at all study visits
- Meibomian gland dysfunction in both eyes based on total meibomian gland score
- None to mild dry eye symptoms based on Ocular Surface Disease Index score
- Tear film interferometry assessment of 100 units or less
Exclusion Criteria:
- Systemic disease conditions that causes dry eye
- Use of systemic medications known to cause dry eye
- Use of other MGD or dry eye treatments except for over the counter lubricants or dietary supplements
- History of any of the following ocular conditions in the past 3 months: surgery, trauma, Herpes infection, recurrent inflammation, punctal plug insertion or punctal occlusion
- Presence of any of the following active conditions: ocular infection, ocular inflammation, moderate to severe allergic conjunctivitis, severe eyelid inflammation, eyelid abnormality that affects lid function, or ocular surface abnormality that compromises corneal integrity
- Participation in another ophthalmic drug or device trial in the past month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LipiFlow Pre-treatment
Subjects randomized to the LipiFlow Pre-Treatment group receive a 12-minute LipiFlow System treatment for MGD in both eyes one month prior to cataract surgery.
|
The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
Other Names:
|
NO_INTERVENTION: Untreated Control
Subjects randomized to the untreated control group receive no MGD treatment prior to cataract surgery.
|
|
EXPERIMENTAL: LipiFlow Post-treatment
Subjects in the untreated control group receive a 12-minute crossover treatment with the LipiFlow System in both eyes three months after cataract surgery.
|
The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Total Meibomian Gland Score
Time Frame: Baseline and 3 Months post-surgery
|
The primary endpoint is the mean change in total meibomian gland score in the Pre-treatment group compared to the Untreated group from Baseline after cataract surgery. Meibomian gland assessment was performed to evaluate the function of the meibomian glands based on the secretion characteristics from the gland orifices along the lower eyelid. Under a slit-lamp biomicrosope, the gland orifices were evaluated using a handheld instrument, Meibomian Gland Evaluator. This instrument provided a standardized method of applying the same amount of pressure and for each eye to ensure measurement consistency. A total of 15 glands were evaluated including five glands each in the temporal, central and nasal regions of the lower eyelid. For each gland, secretion characteristics were graded as 3 (clear liquid), 2 (cloudy liquid), 1 (inspissated/toothpaste consistency) and 0 (no secretion). The total meibomian gland score is the sum of the grades for all 15 glands with a range of 0 to 45. |
Baseline and 3 Months post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Dry Eye Questionnaire Score From Baseline at 3 Months
Time Frame: Baseline and 3 Months post-surgery
|
Assess for reduction in dry eye symptoms in symptomatic contact lens after LipiFlow treatment in comparison to an untreated control using Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire.
It was defined as the mean change in SPEED score in the LF Treatment group compared to Control group from Baseline to 3 Months.
The symptoms assessed are dryness, grittiness / scratchiness; soreness / irritation; burning / watering; and eye fatigue.
Symptom frequency is on a scale of: 0 (never), 1(sometimes), 2 (often) and 3 (constant).
Symptom severity is on a scale of: 0 (no problems), 1 (tolerable-not perfect but not uncomfortable), 2 (uncomfortable-irritating but does not interfere with my day), 3 (bothersome-irritating and interferes with my day) and 4 (intolerable-unable to perform my daily tasks).
SPEED score is calculated as sum of frequency and severity scores for symptoms over a range from 0 to 28.
A lower SPEED score represents less frequent and/or less severe symptoms.
|
Baseline and 3 Months post-surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Ocular Surface Disease Index (OSDI) Questionnaire Score From Baseline at 3 Months
Time Frame: Baseline and 3 Months post-surgery
|
Dry eye symptoms assessed using the OSDI questionnaire are sensitivity to light, grittiness, pain or soreness, blurred vision and poor vision.
The assessment considers the frequency that problems with the eyes limit performance in reading, driving at night, working with a computer or bank machine, and watching television.
Also, the frequency that eyes feel uncomfortable is assessed in windy conditions, areas with low humidity, and air-conditioned areas.
The frequency scale is: 0 (none of the time), 1 (some of the time), 2 (half of the time), 3 (most of the time) and 4 (all of the time).
The subject can answer not applicable (N/A) if the subject did not experience the situation or condition in the past week.
Total OSDI score is calculated as the sum of frequency scores for all symptoms multiplied by 25 and divided by the number of questions answered with a range from 0 to 100.
A lower OSDI score represents less disability from dry eye symptoms.
|
Baseline and 3 Months post-surgery
|
Mean Change in NEI-VFQ Questionnaire Score From Baseline at 3 Months
Time Frame: Baseline and 3 Months post-surgery
|
The National Eye Institute Visual Function Questionnaire (NEI-VFQ) evaluates frequency or severity of a symptoms and the effect on activities of daily living. The questionnaire has an overall score and 12 subscale scores for general health, general vision, ocular pain, difficulty with near vision activities, difficulty with distance vision activities, social functioning limitations due to vision, mental functioning limitations due to vision, role limitations due to vision, dependency on others due to vision, driving difficulties, color vision and peripheral vision. The NEI-VFQ scores range from 0 to 100 with lower scores indicating more symptoms or difficulty with activities of daily living. The questionnaire is scored by recoding responses to set values on a 0 to 100 scale such that the lowest value is set to 0 and the highest value is set to 100. The overall score is the average of vision subscale scores, excluding general health question. |
Baseline and 3 Months post-surgery
|
Mean Change in Number of MGYLS (Meibomian Glands Yielding Liquid Secretion)
Time Frame: Baseline and 3 Months post-surgery
|
Meibomian gland assessment was performed to evaluate the function of the meibomian glands based on the secretion characteristics from the gland orifices along the lower eyelid at the visits. Under a slit-lamp biomicrosope, the gland orifices were evaluated using a handheld instrument, Meibomian Gland Evaluator, to apply gentle pressure along the eyelid margin. This instrument provided a standardized method of applying the same amount of pressure at each visit and for each eye to ensure measurement consistency. The number of meibomian glands yielding liquid secretion (MGYLS) (i.e., cloudy or clear liquid with a grade of 2 or 3) was counted out of the 15 glands assessed with a range of 0 to 15. A higher total meibomian gland score or higher number of MGYLS reflects less meibomian gland dysfunction. |
Baseline and 3 Months post-surgery
|
Mean Change in Tear Break-up Time (TBUT)
Time Frame: Baseline and 3 Months post-surgery
|
The Investigator or designee measures tear break-up time (TBUT) under a slit-lamp biomicroscope following instillation of fluorescein dye in the eye using the Dry Eye Test (DET) method. Tear film break-up is defined as the first observed break-up of the tear film following the third blink. Using a stopwatch to record the time, start the stopwatch as soon as the subject opens his/her eyes after the third blink and stop the stopwatch when the first break-up of the tear film is observed. Any values recorded as greater than 20 seconds were converted to 20 seconds in the analysis. Three separate measurements were taken for each eye and were averaged for analysis. A higher tear break-up time indicates better tear film stability. |
Baseline and 3 Months post-surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Christy Stevens, OD, MPH, TearScience
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LF005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Syndrome
-
Olympic Ophthalmics, Inc.RecruitingMicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye SyndromeUnited States
-
Fidia Farmaceutici s.p.a.RecruitingDry Eye Syndrome (DES)Italy
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
Santen SASCompletedModerate to Severe Dry Eye SyndromeFrance
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Applied Science & Performance InstituteTrue Eye Experts - New Tampa; True Eye Experts - Lutz; True Eye Experts - South...CompletedDry Eye | Dry Eye SyndromesUnited States
-
OphRx Ltd.CompletedDry Eye SyndromesIsrael
-
University of New MexicoWithdrawn
-
Laboratorios Sophia S.A de C.V.Active, not recruitingDry Eye SyndromesMexico
-
GL Pharm Tech CorporationCompleted
Clinical Trials on LipiFlow Pre-Treatment
-
TearScience, Inc.CompletedDry Eye | Meibomian Gland DysfunctionUnited States, Canada
-
Vienna Institute for Research in Ocular SurgeryRecruiting
-
Indiana UniversityIndiana University School of OptometryCompleted
-
Institut Paoli-CalmettesNovartis PharmaceuticalsRecruitingAdvanced or Metastatic Breast Cancer (BC)France
-
TearScience, Inc.CompletedDry Eye Syndromes | ChalazionUnited States
-
Novoxel Ltd.CompletedDry Eye | Dry Eye Syndromes | Meibomian Gland DysfunctionIsrael
-
Samsung Medical CenterUnknownDry EyeKorea, Republic of
-
Hacettepe UniversityCompleted
-
Aier School of Ophthalmology, Central South UniversityUnknown
-
Center Eugene MarquisNot yet recruiting